Silo Pharma's Novel PTSD Approach & Risky Crypto Bet: A Deep Dive

NEW YORK, NY – November 17, 2025 – Silo Pharma Inc. (Nasdaq: SILO) is attempting a high-wire act – pioneering a new approach to treating Post-Traumatic Stress Disorder (PTSD) while simultaneously embracing a largely untested strategy of integrating cryptocurrency into its core financial model. The developmental-stage biopharmaceutical company recently announced a partnership with Allucent, a clinical research organization, to support the preparation of an Investigational New Drug (IND) application for SPC-15, an intranasal prophylactic intended to treat PTSD. However, the company's foray into digital assets is drawing scrutiny and raising questions about long-term viability.

A Nasal Spray for a Silent Epidemic

PTSD affects millions globally, yet effective treatments remain limited. Current therapies often struggle with low adherence rates and incomplete symptom relief. Silo Pharma believes SPC-15, a serotonin 4 receptor agonist delivered via nasal spray, could offer a significant improvement. "The goal is to increase resilience to stress, rather than simply addressing the symptoms after trauma occurs,” explained one industry analyst. The company is pursuing the FDA’s 505(b)(2) regulatory pathway, which can expedite approval for drugs with well-established pharmacological profiles or mechanisms.

Allucent’s involvement is crucial. The CRO brings decades of experience in neuroscience drug development, including expertise in navigating the complexities of clinical trials and regulatory submissions. Recent preclinical data has been promising, with large animal safety studies confirming a favorable safety profile and supporting the viability of the intranasal delivery method. Silo Pharma has also secured several key patents related to SPC-15 technology, including one covering pharmacological prophylactics against stress-induced affective disorders in females. This suggests a targeted approach to addressing PTSD in a gender-specific manner. However, a critical factor will be demonstrating robust efficacy in human clinical trials, which are anticipated to begin following FDA approval of the IND application in 2026. “Success in preclinical studies doesn't guarantee success in humans,” cautioned one medical expert. “The company needs to show significant clinical benefit to differentiate SPC-15 from existing treatments.”

Balancing Innovation with Cryptocurrency Risk

What sets Silo Pharma apart from its peers is its unconventional financial strategy. Unlike most biopharmaceutical companies that rely on traditional funding sources, Silo Pharma has embraced cryptocurrency as a central part of its treasury management. The company holds a portfolio of digital assets, including Bitcoin, Ethereum, and Solana, with the aim of generating yield through staking and capital appreciation. This strategy, launched in August 2025, is based on the belief that cryptocurrencies offer a hedge against financial volatility and a store of value for the future. The company has partnered with Fireblocks, an institutional digital asset custodian, to ensure the security of its holdings and has established a Crypto Advisory Board to guide its investment strategy.

However, this foray into digital assets is not without risk. The cryptocurrency market is notoriously volatile, and prices can fluctuate dramatically. A significant downturn in the market could have a devastating impact on Silo Pharma’s financial position. Furthermore, the regulatory landscape surrounding cryptocurrencies is still evolving, and there is a risk of increased scrutiny or stricter regulations. “It’s a high-risk, high-reward strategy,” said one financial analyst. “While cryptocurrencies could potentially offer significant returns, they also expose the company to a level of financial uncertainty that most biopharmaceutical firms would avoid.” Silo Pharma’s stock has struggled in recent months, with a significant decline in share price and concerns about its ability to maintain Nasdaq compliance. This raises questions about whether the company’s cryptocurrency strategy is helping or hindering its long-term prospects. The company’s current ratio, while currently strong at 6.07, is heavily reliant on the value of these digital assets.

Navigating a Complex Future

Silo Pharma’s journey is a testament to the increasing convergence of biotechnology and digital finance. The company is attempting to disrupt the PTSD treatment landscape while simultaneously embracing a largely unproven financial strategy. Whether this ambitious undertaking will succeed remains to be seen. The company's financial stability is tenuous, and it is heavily reliant on maintaining investor confidence and navigating a volatile cryptocurrency market. The approval of SPC-15 and the successful execution of its clinical development program will be critical. “The company faces a significant challenge,” said one industry observer. “It needs to demonstrate that it can deliver on its scientific promises while also managing the risks associated with its cryptocurrency investments.” The next year will be crucial for Silo Pharma, as it seeks to advance SPC-15 through clinical trials and solidify its position in a rapidly evolving market.